Counterpoint: Is pharmacokinetic or pharmacodynamic monitoring of calcineurin inhibition therapy necessary? - Individual Prediction and Prevention of Risks of Immunosuppressive Therapies in Transplantation Access content directly
Journal Articles Clinical Chemistry Year : 2010

Counterpoint: Is pharmacokinetic or pharmacodynamic monitoring of calcineurin inhibition therapy necessary?

Abstract

PK monitoring of cyclosporine and tacrolimus has been improved over the years by a try-and-error process. Although formal clinical evidence is weak, TAC monitored on C0 and/or CsA monitored on C2 have become the basis of immunosuppression in most countries, associated with very low rejection rates during the first year post-transplant. However, it could possibly (and in the present era of CNI minimization, may need to) be improved further by means of more sophisticated approaches, such as AUC Bayesian estimation, preferably after validation by randomized prospective trials. Clinical evidence in favor of CNI PD monitoring is currently at the lowest level and clinical experience is close to nil. Before it can be envisaged as a treatment personalization tool in organ transplantation, many questions still have to be answered, starting with the best marker of immunity to use, the influence of the physiological changes and immune system stimulation occurring post-transplantation, the effects of each immunosuppressive drug and their combinations on these biomarkers, and leading up to the relationships between such markers and clinical outcome. Continued efforts should also be made for a better understanding of the impact of pharmacogenetics on immunosuppressant benefit/risk ratio.
Fichier principal
Vignette du fichier
P_Marquet_Counterpoint_HAL-Inserm.pdf (51.84 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00466361 , version 1 (23-03-2010)

Identifiers

Cite

Pierre Marquet. Counterpoint: Is pharmacokinetic or pharmacodynamic monitoring of calcineurin inhibition therapy necessary?. Clinical Chemistry, 2010, 56 (5), pp.736-9. ⟨10.1373/clinchem.2009.138693⟩. ⟨inserm-00466361⟩
33 View
189 Download

Altmetric

Share

Gmail Facebook X LinkedIn More